CIDPUSA.ORG

Autoimmune diseases

God Our Guide

Main Links Cidpusa.org

Home page

Autoimmune Diseases Guide

F.A.Q.

services contact page

Prevent Breast Cancer

Some things you can't avoid when it comes to breast cancer risk, such as your age, genetic makeup and environmental exposures. But other breast cancer risk factors are well within your control. Recent studies indicate that lifestyle choices are more influential than genetic pre-disposition in the development of breast cancer. Employing preventive health measures can't guarantee that you won't develop breast cancer, but it's a step in the right direction.

Autoimmune diseases such as type 1 diabetes and rheumatoid arthritis (RA) are caused when immune cells known as lymphocytes attack our own body tissues.


Depletion of the B cell subset of lymphocytes using an antibody specific for the protein CD20 has been shown to be effective for the treatment of RA. The effectiveness of such an approach for the treatment of type I diabetes is not known, largely because the reagents to address this question in preclinical models have been lacking.

This problem has now been overcome by Li Wen and colleagues from Yale School of Medicine, New Haven, who have developed the necessary tools and shown that depletion of B cells can both prevent diabetes and reverse established disease in mice. In the accompanying commentary, Hélène Bour-Jordan and Jeffrey Bluestone from the University of California, San Francisco, highlight the importance of these advances for developing and optimizing the potential of CD20-specific antibodies for the treatment of type 1 diabetes

In the study, autoimmune diabetes--susceptible mice were engineered such that their B cells expressed human CD20. Depletion of B cells in these mice before they showed signs of diabetes, using a single dose of a CD20-specific antibody, delayed and/or reduced the onset of disease.

Similarly, in mice already showing signs of diabetes, a single dose of the CD20-specific antibody reversed disease in a substantial proportion of the mice. Furthermore, the mechanism behind the protection afforded by CD20-specific antibody treatment was shown to be associated with increased numbers of regulatory T cells and B cells.

The article "Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in

Rituximab preserved beta-cell function in type 1 diabetes

Patients with type 1 diabetes treated with a four-dose course of rituximab experienced partially preserved beta-cell function during one year, showing that a therapy that targets beta cells may have a positive effect on beta-cell function in early type 1 diabetes.